Close this search box.
Subscriber Log In
Webinar | On demand

2023 Preview

A new year, a fresh outlook for beaten-up biotech companies? There are some hopes that conditions will improve during 2023, though few are expecting a dramatic recovery. View the webinar for expert views on the year ahead, and a look at the challenges and opportunities that will present themselves.

Amy Brown and Edwin Elmhirst from Evaluate Vantage, discuss what the coming year is likely to bring.

Watch the webinar.

Biotech and pharma: from bad to worse, or better in 2023?

Get insights on:

  • Which areas and indications look set to take off in 2023
  • What’s the impact of the macroeconomic landscape on the life sciences market?
  • The big players and the new drugs set to drive growth
  • The latest IPO and dealmaking activity

For the full data you can download the 2023 Preview report.

Amy Brown

Special Reports & Projects Editor, Evaluate


Edwin Elmhirst

Data Journalist, Citeline